These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21150914)

  • 1. Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms.
    Morrison PD; Nottage J; Stone JM; Bhattacharyya S; Tunstall N; Brenneisen R; Holt D; Wilson D; Sumich A; McGuire P; Murray RM; Kapur S; Ffytche DH
    Neuropsychopharmacology; 2011 Mar; 36(4):827-36. PubMed ID: 21150914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine.
    Murray CH; Frohlich J; Haggarty CJ; Tare I; Lee R; de Wit H
    Neuropsychopharmacology; 2024 Jun; 49(7):1120-1128. PubMed ID: 38287172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary investigation of childhood anxiety/depressive symptomatology and working memory across multiple units of analysis.
    Kavanaugh BC; Fryc A; Temereanca S; Tirrell E; Oberman L; Carpenter LL; Spirito A
    Psychiatry Res; 2021 Apr; 298():113786. PubMed ID: 33636515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplexed Levels of Cognitive Control through Delta and Theta Neural Oscillations.
    Pagnotta MF; Riddle J; D'Esposito M
    J Cogn Neurosci; 2024 May; 36(5):916-935. PubMed ID: 38319885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of marathon running on resting-state EEG activity: a longitudinal observational study.
    Moussiopoulou J; Pross B; Handrack M; Keeser D; Pogarell O; Halle M; Falkai P; Scherr J; Hasan A; Roeh A
    Eur J Appl Physiol; 2024 Apr; 124(4):1311-1321. PubMed ID: 38019317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new interpretation of P300 responses upon analysis of coherences.
    Güntekin B; Başar E
    Cogn Neurodyn; 2010 Jun; 4(2):107-18. PubMed ID: 21629584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of biofield therapy in the human brain.
    Uchida S; Iha T; Yamaoka K; Nitta K; Sugano H
    J Altern Complement Med; 2012 Sep; 18(9):875-9. PubMed ID: 22816385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case Series: Psychotic Disorder Associated With Gummies Containing Delta-8-Tetrahydrocannabinol.
    Spiegel DR; Bard J; Ralston M; Crafton W; Osman A; Hager K; Suryadevara P
    J Clin Psychopharmacol; 2024 Jul; ():. PubMed ID: 39008848
    [No Abstract]   [Full Text] [Related]  

  • 9. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
    Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
    J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date.
    Sami MB; Rabiner EA; Bhattacharyya S
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1201-24. PubMed ID: 26068702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
    Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
    Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC).
    Bossong MG; Jansma JM; Bhattacharyya S; Ramsey NF
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():53-69. PubMed ID: 24380726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of psilocybin response in healthy volunteers.
    Studerus E; Gamma A; Kometer M; Vollenweider FX
    PLoS One; 2012; 7(2):e30800. PubMed ID: 22363492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.
    Scheyer A; Yasmin F; Naskar S; Patel S
    Neuropsychopharmacology; 2023 Jan; 48(1):37-53. PubMed ID: 36100658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Epigenetics of Psychosis: A Structured Review with Representative Loci.
    Miller CL
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance-Induced Psychoses: An Updated Literature Review.
    Fiorentini A; Cantù F; Crisanti C; Cereda G; Oldani L; Brambilla P
    Front Psychiatry; 2021; 12():694863. PubMed ID: 35002789
    [No Abstract]   [Full Text] [Related]  

  • 19. Human Pharmacokinetics and Adverse Effects of Pulmonary and Intravenous THC-CBD Formulations.
    Meyer P; Langos M; Brenneisen R
    Med Cannabis Cannabinoids; 2018 Jun; 1(1):36-43. PubMed ID: 34676320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in Electroencephalography Theta as Candidate Biomarkers of Acute Cannabis Intoxication.
    Richard CD; Poole JR; McConnell M; Meghdadi AH; Stevanovic-Karic M; Rupp G; Fink A; Schmitt R; Brown TL; Berka C
    Front Neurosci; 2021; 15():744762. PubMed ID: 34671242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.